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Genome wide association study of 
uric acid in Indian population and 
interaction of identified variants 
with Type 2 diabetes
Anil K Giri1,2, Priyanka Banerjee1, Shraddha Chakraborty1,2, Yasmeen Kauser1,2, 
Aditya Undru1,2, Suki Roy1, Vaisak Parekatt1, Saurabh Ghosh3, Nikhil Tandon4 & 
Dwaipayan Bharadwaj1,2,†
Abnormal level of Serum Uric Acid (SUA) is an important marker and risk factor for complex diseases 
including Type 2 Diabetes. Since genetic determinant of uric acid in Indians is totally unexplored, we 
tried to identify common variants associated with SUA in Indians using Genome Wide Association 
Study (GWAS). Association of five known variants in SLC2A9 and SLC22A11 genes with SUA level in 
4,834 normoglycemics (1,109 in discovery and 3,725 in validation phase) was revealed with different 
effect size in Indians compared to other major ethnic population of the world. Combined analysis of 
1,077 T2DM subjects (772 in discovery and 305 in validation phase) and normoglycemics revealed 
additional GWAS signal in ABCG2 gene. Differences in effect sizes of ABCG2 and SLC2A9 gene variants 
were observed between normoglycemics and T2DM patients. We identified two novel variants near 
long non-coding RNA genes AL356739.1 and AC064865.1 with nearly genome wide significance level. 
Meta-analysis and in silico replication in 11,745 individuals from AUSTWIN consortium improved 
association for rs12206002 in AL356739.1 gene to sub-genome wide association level. Our results 
extends association of SLC2A9, SLC22A11 and ABCG2 genes with SUA level in Indians and enrich the 
assemblages of evidence for SUA level and T2DM interrelationship.
Uric acid is a by-product of oxidation of purine. SUA levels have been used as biological marker for many disor-
ders like gout, arthritis, kidney functions1,2, hypertension, metabolic disorders and type 2 diabetes3,4. Studies have 
established SUA as an important stake holder regarding health issues of particular population. Hence it creates a 
necessity to study factors affecting SUA level of a population.
The levels of uric acid in an individual is a combined result of genetic factors and multitude of life style related 
factors like food habit, exercise, work type and means of transportation5–8. Indians differ in their food habit, living 
style and genetic constitutions from other ethnic populations in the world9–11.
Genetic studies have established a heritability of 40–70% for SUA level suggesting stronger role of genetic 
factors in determining SUA level12. Major part of genetic factors contributing to the SUA level has not been well 
understood as few number of genetic studies have been performed in limited populations and most of them being 
of European ethnicity. GWAS conducted on Japanese, Chinese, African American and Amish populations have 
established association of loci in urate transporter genes like SLC2A9, ABCG2, SLC22A1 and SLC22A1213–19. 
Large scale meta-analysis conducted by Asian Genetic Epidemiology Network (AGEN) has included some sam-
ples from the Singapore Indian Study (SINDI) and identified loci in transcription factor MAF for SUA level20. 
Another large scale meta-analysis conducted by Global Urate Genetics Consortium15 identified 18 new loci asso-
ciated with SUA level near TRIM46, INHBB, SFMBT1, TMEM171, VEGFA, BAZ1B, PRKAG2, STC1, HNF4G, 
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A1CF, ATXN2, UBE2Q2, IGF1R, NFAT5, MAF, HLF, ACVR1B-ACVRL1 and B3GNT4 genes. Their analysis in 
8380 samples of Indian ancestry showed association of variants in SLC2A9, ABCG2, SLC22A11, GCKR, SLC17A1 
gene at genome wide significance level. None of these study subjects were living in India. Both of the studies 
include Indian subjects from different ethnicities including Dravidian samples. This reflects a lack of independent 
studies conducted on Indian subjects for SUA level globally despite several waves of GWAS for different pheno-
type in different population. There is no separate genetic epidemiological study for uric acid levels in Indian pop-
ulation till date. Hence, genetic study in Indian population becomes necessary and provides a unique opportunity 
to explore the population specific genetic factors affecting uric acid level related to Indians.
Some of the identified genetic loci associated with SUA levels are found to show interactions with several 
phenotypes like sex, age and Body Mass Index (BMI)21,22. A recent epidemiological study showed a stronger 
association of SUA level with impaired fasting glucose suggesting a complex relationship between uric acid patho-
physiology and glucose level23. T2DM is a condition where glucose metabolism of the individual gets impaired 
along with several other biochemical and signaling pathways. Another report showed association of uric acid 
transporter gene SLC2A9 variant rs1014290 with T2DM status24. This suggests a plausible inter-relation between 
SUA related genetic factors and T2DM. However, there is no concrete study till date investigating the interaction 
between SUA genetics and T2DM. The present study aims at identification of common variants associated with 
SUA levels by two-staged Genome Wide Association Study (GWAS) in 4,834 healthy Indians of Indo-European 
ethnicity living in Northern part of India. Further, it extends its interest to explore the variability in effect of iden-
tified GWAS variants under altered condition (T2DM).
Results
Genome wide association analysis of SUA. After stringent quality control, we analyzed a total of 
5,39,662 genetic markers in discovery phase for their association with SUA levels in 1,109 individuals using linear 
regression. A good agreement was observed between the theoretical p-value distribution and calculated p-values 
using QQ plot as shown in Fig. 1. The genomic inflation factor for the fitted model was calculated as 1.006 that 
indicates homogeneity of analyzed samples. SPATA13 variants (rs9511097) were detected as most significant sig-
nal (Effect size = − 16.35, p-value = 2.19 × 10−6) in discovery phase (Fig. 2). Along with the earlier known GWAS 
signals for SUA, SNPs with p-values< 10−4 from discovery phase were genotyped in 3,725 Indian samples for rep-
lication phase. 4 SNPs associated with SUA level in 1st phase had to be removed before final analysis in replication 
phase owing to their failure in quality control.
Meta-analysis was performed in 4,834 normoglycemic individuals and results yielded five SNPs in two dif-
ferent genes (SLC2A9 and SLC22A11) associated with SUA levels at genome wide significance levels (Table 1, 
Fig. 2). Variant rs3775948 in SLC2A9 gene showed most significant association with SUA levels in Indians 
(p-value = 1.7 × 10−19) that is in line with earlier findings in Japanese and African American population 
(Table 2)13,14. Another three detected variants in SLC2A9 gene include rs16890979 (p-value = 2.62 × 10−18), 
rs11722228 (p-value = 7.34 × 10−16) and rs737267 (p-value = 2.71 × 10−16). The other genetic variant (rs2078267) 
attaining genome wide significant level was found to reside in SLC22A11 gene (p-value = 3.26 × 10−11) (Table 1, 
Fig. 2). We also noticed almost genome wide association for missense variant rs2231142 (p-value = 7.82 × 10−8) 
in ABCG2 gene (Table 1).
Conditional analysis to examine independence of signals in SLC2A9. To examine independent 
association of signals in SLC2A9, conditional analysis of cumulative data (discovery and replication phase) was 
Figure 1. Quantile-quantile (QQ) plot for the calculated p-value in discovery phase. The -log10 of p-values 
observed for the association of SNPs in discovery phase genome wide association analysis under additive model 
adjusted for age, sex BMI, PC1 and PC2 (black symbols) are plotted against the theoretical -log10 p-values 
expected under the null hypothesis (red line). The genomic control inflation factor (λ ) was estimated to be 1.06.
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performed using additive model and result showed that rs3775948 (SLC2A9) as the lead SNP (Supplementary 
Table S1). Following conditional analysis for rs3775948, none of remaining three SNPs showed association at 
genome wide significance level but remained significant at sub-GWAS level (rs16890979, p-value = 1.078 × 10−7; 
rs737267, p-value = 1.86 × 10−5 and rs11722228, p-value = 1.64 × 10−5) (Supplementary Table S1). Results also 
indicated moderate linkage disequilibrium between rs3775948 and rs16890979 (R2 = 0.5).
Status of earlier known GWAS signals. To examine the status of SUA associated variants across various 
populations, we compared effect size and association strength of known signals reported in GWAS catalogue 
among Indians and other major ethnic populations. Variants in SLC22A12 gene (rs505802, P = 5.18 × 10−6) and 
GCKR gene (rs1260326, P= 7.7 × 10−4 and rs780094, P= 5.83 × 10−3) achieve sub-genome wide significance level 
in Indian population (Table 2). In addition, nominal association of variant rs1165205 in SLC17A3 gene (P = 0.03) 
with SUA level was detected in studied samples, whereas, markers in PDZK1 (rs1967017), ATXN2 (rs653178), 
SLC17A1 (rs1165196), BTF3P7-RREB (rs675209) and SLC16A9 (rs12356193) could not be replicated (Table 2).
Furthermore, difference in the effect size of genetic variants was also observed across population. Variants 
rs3775948 (SLC2A9, G allele) has been associated with decrease of uric acid level in Japanese population (Table 2) 
and African American population14, however it has higher effect size in Indians. Another non-synonymous cod-
ing SNP rs16890979 (A allele-Val253Ile) in exon 8 of SLC2A9 gene has been associated with decrease in SUA 
levels in Chinese, European and Amish population17–19. The effect size of this variant in Indians is less than 
Caucasian and Amish population and higher than Chinese population (Table 2). The variant rs2078267 (A allele) 
in SLC22A11 gene has higher effect size in Indians than in Caucasian population. Furthermore, ABCG2 missense 
variant (rs2231142, Gln141Lys) has higher effect size in Indians than Caucasian, Chinese and Japanese popula-
tion as shown in Table 2.
Increase in number of GWAS signals with advent of type 2 diabetes. The effect of increasing 
sample size on the status of SUA associated genetic variants was examined. For this, meta-analysis of summary 
statistics obtained from association of T2DM subjects was conducted along with summary statistics from nor-
moglycemic subjects. Analysis in a total sample of 5,911 individuals consisting of 4,834 normoglycemic subjects 
and 1,077 T2DM subjects improved the association of missense variant rs2231142 in ABCG2 from 7.82 × 10−8 
(Table 1) in normoglycemic subjects to 1.31 × 10−10 in combined sample (Table 3). Inclusion of T2DM samples 
in combined meta-analysis did not affect homogeneity of association (Table 3) and no difference in minor allele 
frequency (MAF) of rs2231142 was seen in normoglycemic and T2DM samples (Table 4).
SUA variants have higher effect size in T2DM subjects. To unravel the possible inter-relation of SUA 
associated genetic variants with type 2 diabetes, we sought to examine whether these signals have different fate 
and effects in T2DM patients. We compared the effect sizes of signals that achieved GWAS level significance 
and were also significantly associated (p-value = 0.05) with SUA in T2DM subjects. Analysis revealed significant 
differences in the effect size of these variants between T2DM patients and normoglycemic subjects. Variants 
rs16890979 (A allele, d = − 2.74) and rs737267 (A allele, d = − 3.26) in SLC2A9 genes possess higher effect size 
in presence of T2DM. Additionally, ABCG2 gene variant rs2231142 (A allele, d = 1.71) was also reported to be 
associated with high SUA levels in T2DM patients (Table 4). Therefore, higher effect sizes of SUA genetic determi-
nants in T2DM suggest possible interaction with T2DM pathophysiology. Joint analysis including T2DM patients 
and normoglycemic subjects adjusted for age, sex, BMI and diabetic status also confirmed the association of 
Figure 2. Manhattan plot for the SNPs associated with SUA levels in discovery phase. The -log10 p-values 
for association of genotyped SNPs are plotted as a function of genomic position (National Center for 
Biotechnology Information Build 37). The p-values were determined using logistic regression adjusted for 
age, sex, BMI, PC1 and PC2 in discovery phase analysis. Each chromosome (Chr) has been represented with a 
unique color.
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above six variants with SUA level at genome wide significance in Indian population. It also confirmed association 
of rs2231142 variant in ABCG2 gene with SUA level in Indians as shown in Table 5.
Genotypes based on individual SNPs strongly correlate with average SUA level of subjects in Indians as 
shown in Supplementary Fig. S2. The cumulative effect analysis also revealed strong association of genetic score 
with SUA level (p-value = 2 × 10−16). Each additional allele causes a 6.45 unit increase in SUA level as shown in 
Supplementary Fig. S3.
Enrichment analysis of the significant genes. Enrichment analysis was performed for the genes found 
significant in meta-analysis and result showed urate metabolic process as significantly enriched process in Indian 
population (Supplementary Table S2). Enrichment of six genes (GCKR, SLC2A9, ABCG2, SLC22A11, SLC22A12 
and SLC17A3) were observed against 11 genes (PRPS1, SLC17A1, SLC22A11, SLC2A9, PNP, SLC22A12, SLC16A9, 
Marker CHR BP
Nearest 
Gene Al/A2
Discovery Phase Validation Phase Meta-analysis
Effect size (95% CI) p-value Effect size (95% CI) p-value Effect size (95% CI) p-value Dir
HetI 
Sq
Het-P 
Val
rs3775948* 4 9995182 SLC2A9 G/C − 11.96  (− 18.95–− 4.96) 8.41 × 10
−4 − 16.49  
(− 20.31–− 12.67) 3.68 × 10
−17 − 15.45  
(− 18.80–− 12.1) 1.70 × 10
−19 − − 19.3 0.27
rs16890979* 4 9922167 SLC2A9 A/G − 12.53  (− 20.2–− 4.86) 1.41 × 10
−3 − 16.99  
(− 21.07–− 12.92) 3.85 × 10
−16 − 16.01  
(− 19.61–− 12.41) 2.62 × 10
−18 − − 1.3 0.31
rs737267* 4 9934744 SLC2A9 A/C − 11.36  (− 18.65–− 4.08) 2.29 × 10
−3 − 15.35  
(− 19.28–− 11.42) 2.51 × 10
−14 − 14.45  
(− 17.91–− 10.99) 2.71 × 10
−16 − − 0 0.35
rs11722228 4 9915741 SLC2A9 A/G 16.06  (9.365–22.76) 2.93 × 10
−6 12.55  
(8.831–16.27) 4.27 × 10
−11 13.38  
(10.13 − 16.63) 7.34 × 10
−16 + + 0 0.37
rs2078267* 11 64334114 SLC22A11 A/G − 8.13  (− 14.6–− 1.66) 0.01
− 11.27  
(− 14.83–− 7.72) 5.65 × 10
−10 − 10.54  
(− 13.66–− 7.43) 3.26 × 10
−11 − − 0 0.41
rs2231142* 4 89052323 ABCG2 A/C 12.36  (0.43–24.3) 0.04
16.78  
(10.22–23.35) 5.58 × 10
−7 15.75  
(10.01–21.50) 7.82 × 10
−8 + + 0 0.52
Table 1.  SNPs showing association with SUA at genome wide significance levels in meta-analysis. 
Chromosomal positions of SNPs are based on National Center for Biotechnology Information genome build 37. 
Alleles presented are indexed to the positive strand. Effect size was calculated with respect to the minor alleles. 
Direction was + + /− − if there was concordance between the discovery and validation phase and + − /− + 
if there was discordance; Association results presented were obtained from genotyped data in 1,109 subjects 
from discovery phase and 3,725 subjects from validation phase.*Earlier reported variants taken in replication 
despite their higher p-value (> 10−4 ) in discovery phase. Meta analysis has been done using METAL using fixed 
effect inverse variance method. CHR: chromosome; BP: Base pair position; Dir.: direction; Het-P: p-value for 
heterogeneity in effect sizes in meta-analysis; Het-I Sq: Chi-square value for heterogeneity test.
Nearest 
Gene SNP
Indians Chinese Japanese Caucasians
MAF
Effect 
size p-value MAF
Effect 
size p-value Ref MAF
Effect 
size p-value Ref MAF Effect size p-value Ref
SLC2A9 rs3775948 0.31 (G) − 15.45 1.70 × 10−19 NA NA NA NA 0.59 (C) 0.18 2 × 10−65 13 NA NA NA NA
SLC2A9 rs16890979 0.24 (A) − 16.01 2.62 × 10−18 0.02 (T) − 0.02 0.29 17 0.01 (T) − 0.18 3.07 × 10−2 13 0.29 (T) − 20.22 3.6 × 10−189 40
SLC2A9 rs737267 0.27 (A) − 14.45 2.71 × 10−16 NA NA NA NA NA NA NA NA 0.31(T) − 0.88 3.0 × 10−9 41
SLC2A9 rs11722228 0.35 (A) 13.38 7.34 × 10−16 0.31 (T) 0.03 3.68 × 10−6 17 0.45 (T) 0.16 7.09 × 10−24 13 0.50 (T) 9.93 1.8 × 10−75 40
SLC22A11 rs2078267 0.41 (A) − 10.54 3.26 × 10−11 NA NA NA NA 0.01 2.58 0.64 13 0.51 (T) − 4.34 9.0 × 10−38 15
ABCG2 rs2231142 0.08 (A) 15.75 7.82 × 10−8 0.29 (T) 0.05 1.2 × 10−9 17 0.31 (T) 0.12 1.62 × 10−13 13 0.11 (T) 10.29 3.1 × 10−26 40
SLC22A12 rs505802 0.41 (G) 7.36 5.18 × 10−6 0.23 (T) − 0.01 0.20 17 0.18 (T) − 0.23 1.00 × 10−31 13 0.30 (T) − 3.57 2.0 × 10−9 40
GCKR rs1260326 0.23 (A) 6.24 7.70 × 10−4 NA NA NA NA NA NA NA NA 0.41 (T) 4.40 7.0 × 10−44 15
GCKR rs780094 0.24 (A) 5.10 5.83 × 10−3 0.44 (T) 0.01 0.01 17 0.43 (T) 0.04 5.12 × 10−6 13 0.42 (T) 2.97 1.4 × 10−9 40
SLC17A3 rs1165205 0.50 (A) 3.48 0.03 0.19 (T) − 0.01 0.14 17 0.16 (T) − 0.07 5.04 × 10−4 13 0.47 (T) − 5.35 4.0 × 10−29 18
SLC17A1 rs1165196 0.46(G) − 2.72 0.09 NA NA NA NA NA NA NA NA 0.49 (G) − 6.25 5.0 × 10−25 16
RREB rs675209 0.43 (G) − 2.55 0.12 NA NA NA NA NA NA NA NA 0.27 (T) 3.64 7.0 × 10−23 15
ATXN2 rs653178 0.10 (G) 4.07 0.12 NA NA NA NA NA NA NA NA 0.51 (T) − 2.08 7.0 × 10−12 15
SLC16A9 rs12356193 0.13 (G) − 1.60 0.50 NA NA NA NA NA NA NA NA 0.83 (A) 4.76 1.0 × 10−8 40
PDZK1 rs1967017 0.33 (G) − 0.92 0.59 NA NA NA NA NA NA NA NA 0.47 (T) 3.33 4.0 × 10−8 16
Table 2.  Comparison of effect size of known GWAS variants associated with SUA across different ethnic 
population. Effect sizes of current study (Indians) have been obtained from meta-analysis of normoglycemic 
subjects. Effect sizes of current study (Indians) and the source study are presented with respect to the minor 
allele as presented in MAF column of respective population. p-value indicates association with SUA levels. NA: 
not available; MAF: Minor allele frequency; Ref: Reference.
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GCKR, SLC17A3, ABCG2 and LRC16A) present in human genome under urate metabolic process (accession 
number GO:0046415) with IMP (Inferred from mutant phenotype) category.
Identification of novel signals in healthy subjects. Although our analysis in healthy subjects could 
not detect any novel genetic variants associated with SUA levels at genome wide significance levels, we have 
identified three novel loci (rs12206002, rs993701, rs1445305) in two different genes (UTRN-AL356739.1, 
AC064865.1-RPL6P5) at sub-genome wide significance levels (p-value< 10−5, 10−4) (Supplementary Table S3). 
These loci could not be detected at genome wide levels even when our study was sufficiently powered (> 98%) to 
detect these associations (Supplementary Fig. S1).
SN Marker Gene A1/A2
Discovery Phase Validation Phase Meta-analysis
Effect size (95% CI) p-value Effect size (95% CI) p-value Effect size (95% CI) p-value Dir
Het 
I Sq
Het-P 
Val
1 rs16890979 SLC2A9 A/G − 16.07 (− 22.83–− 9.316) 3.36 × 10−6 − 17.15 (− 21.18–− 13.12) 1.02 × 10−16 − 16.87 (− 20.33–− 13.40) 1.32 × 10−21 − − 0 0.79
2 rs737267 SLC2A9 A/C − 15.07 (− 21.52–− 8.614) 5.01 × 10−6 − 15.67 (− 19.55–− 11.78) 3.61 × 10−15 − 15.51 (− 18.84–− 12.18) 6.96 × 10−20 − − 0 0.88
3 rs3775948 SLC2A9 C/G − 10.34 (− 16.45–− 4.23) 9.27 × 10−4 − 15.93 (− 19.7–− 12.15) 1.77 × 10−16 − 14.39 (− 17.60–− 11.18) 1.58 × 10−18 − − 57 0.13
4 rs11722228 SLC2A9 A/G 12.66 (6.685–18.64) 3.44 × 10−5 12.68 (9.005–16.36) 1.60 × 10−11 12.67 (9.54–15.81) 2.21 × 10−15 + + 0 1.00
5 rs2231142 ABCG2 A/C 21.00 (10.91–31.08) 4.67 × 10−5 16.75 (10.2–23.3) 5.60 × 10−7 18.01 (12.52–23.50) 1.31 × 10−10 + + 0 0.49
6 rs2078267 SLC22A11 A/G − 6.61 (− 12.37–− 0.84) 0.02 7.72 (− 11.25–− 4.20) 1.78 × 10−5 − 7.42 (− 10.43–− 4.41) 1.31 × 10−6 − − 0 0.75
Table 3.  Addition of T2DM subjects revealed addition SNPs associated with SUA at genome wide 
significance levels in meta-analysis. Association results presented were obtained from genotyped data in 1,881 
individuals including 1,109 healthy and 772 T2DM subjects from discovery phase and 4,030 subjects including 
3,725 healthy and 305 T2DM subjects from validation phase. Effect size was calculated with respect to the 
minor alleles. Direction was + + /− − if there was concordance between the discovery and validation phase and 
+ − /− + if there was discordance. Meta analysis has been done using METAL using fixed effect inverse variance 
method. Dir: direction; Het-P: p-value for heterogeneity in effect sizes in meta-analysis; Het-I Sq: Chi-square 
value for heterogeneity test.
Marker CHR BP
Nearest 
Gene Al/A2
Healthy Individuals T2DM
MAF 
(A1) Effect size (95% CI ) p-value
MAF 
(A1) Effect size (95% CI ) p-value Cohen’s d
rs16890979 4 9922167 SLC2A9 A/G 0.24 − 16.01 (− 19.61–− 12.41) 2.62 × 10−18 0.23 − 23.20 (− 32.58–− 13.81) 1.27 × 10−6 − 2.74
rs737267 4 9934744 SLC2A9 A/C 0.27 − 14.45 (− 17.91–− 10.99) 2.71 × 10−16 0.27 − 22.62 (− 31.56–− 13.68) 7.07 × 10−7 − 3.26
rs2231142 4 89052323 ABCG2 A/C 0.08 15.75 (10.01–21.50) 7.82 × 10−8 0.08 22.83 ( 8.19–37.47) 2.23 × 10−3 1.71
Table 4.  Comparison of association status of SUA associated variants in healthy subjects and T2DM 
subjects. Association results presented in healthy individuals denote meta-analysis of 4,834 individuals from 
discovery and validation phase. Association results presented in T2DM subjects were presented for 1,077 
diabetic individuals. Effect size was calculated with respect to the minor alleles. p-value shown here is obtained 
after meta-analysis of samples in discovery phase and replication phase. Cohen’s d was calculated as the ratio of 
mean difference of effect size between T2DM and healthy subject and pooled variance. Cohen’s d (d) value was 
calculated to compare the effect size. Cohen’s d was calculated as the ratio of difference of effect size between 
T2DM and normoglycemic divided by pooled variance of the two effect sizes. Chromosomal positions of SNPs 
are based on National Center for Biotechnology Information genome build 37. CHR: chromosome; BP: Base 
pair position; MAF: Minor allele frequency.
Marker CHR BP
Nearest 
Gene A1/A2 Effect size (95% CI ) p-value
rs16890979 4 9922167 SLC2A9 A/G − 16.93 (− 20.38–− 13.49) 8.28 × 10−22
rs737267 4 9934744 SLC2A9 A/C − 15.59 (− 18.90–− 12.27) 3.82 × 10−20
rs3775948 4 9995182 SLC2A9 G/C − 14.06 (− 17.25–− 10.87) 7.68 × 10−18
rs11722228 4 9915741 SLC2A9 A/G 12.52 (9.41–15.63) 3.56 × 10−15
rs2231142 4 89052323 ABCG2 A/C 17.56 (12.12–23.01) 2.74 × 10−10
rs2078267 11 9934744 SLC22A11 A/G − 8.92 (− 11.9–− 5.95) 4.30 × 10−9
Table 5.  Association status of top signals achieving GWAS significance in joint analysis. Association results 
for joint analysis performed in 5,911 (4,834 normoglycemic and 1,077 T2DM) individuals using genotype 
data for discovery and validation phase. Chromosomal positions of SNPs are based on National Center for 
Biotechnology Information genome build 37. CHR: chromosome; BP: Base pair position MAF. CI: Confidence 
interval.
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Meta-analysis and in-silico replication. The meta-analysis of summary statistics for three novel 
loci (rs12206002, rs993701 and rs1445305) was performed with association data from AUSTWIN consor-
tium. Meta-analysis improved the association status for variant rs12206002 from 8.83 × 10−5 to 7.23 × 10−7 
(Supplementary Table S4). Heterogeneity in effect size of rs12206002 was observed across populations. We did 
not detect any improvement in the association of variant rs993701as it shifted to a meta-analysis p-value of 0.45 
from 1.23 × 10−4 in Indian normoglycemic subjects. Association p-value for variant rs1445305 also increased 
from 9.85 × 10−4 to 0.21 after meta-analysis.
Discussion
Present study is the first genome wide association study for SUA level in Indians. We found association of 
SLC2A9, SLC22A11 and ABCG2 gene variants at genome wide significance level (p-value < 10−8). This is the first 
study to report the differences in effect size of SUA associated genetic variants in SLC2A9 and ABCG2 in T2DM 
patients that suggests involvement of these gene variants in the alteration of uric acid levels in T2DM subjects. 
We also replicated variants in GCKR and SLC17A1 gene at nominal significance levels. All these genes encode 
for transporter proteins. All significant genes explained nearly ~6% of the variance explained in uric acid level. 
This suggests contribution of other genetic, epigenetic and other factors in pathophysiology of uric acid levels in 
Indian population.
Studies have reported that SLC2A9 is expressed in both kidney and liver of human and mice and is upregulated 
in diabetes mice25. The SLC2A9 expression was found to be governed by p53 gene and is mediated by oxidative 
stress26. Oxidative stress play major and deterministic role in patho-physiology of T2DM and has been observed 
to be higher in T2DM patients than healthy controls27. The higher expression of SLC2A9 in diabetic condition 
may be governed by higher oxidative stress in diabetics. In a recent study, Hurba et al. observed that there is no 
significant difference in transport activity of coding rs16890979 (Val253Ile) variant containing protein and wild 
type protein in Xenopus oocyte expression system28. The higher activity of SLC2A9 in T2DM subjects compared 
to normoglycemics may be attributed to higher expression of total SLC2A9 protein in T2DM condition.
Similarly, another significant gene ABCG2 is located at apical membrane of renal proximal tubule and is 
involved in excretion of uric acid in urine. The functional form of ABCG2 protein present at cell membrane is 
homodimer glycosylated protein29,30. The homodimer formation requires proper folding and a disulphide bond 
formation between residues of two monomers in endoplasmic reticulum29. Reducing folding environment has 
found to induce improper folding in Q141K containing protein31. T2DM is a complex disorder where many 
biochemical processes, signaling cascades as well as hormone levels get altered. One of the major consequences 
of T2DM is alteration in redox potential in cellular compartments as well as extracellular spaces32. Study sug-
gests that although there is an increase in oxidative environment of other compartments, the redox potential 
of microsomal vesicles from diabetic mice was found to shift towards more reducing end32. Because of these 
alterations of oxidative environment of microsomal vesicles towards comparatively more reducing environment 
in diabetic patients, more of the Q141K containing protein will be improperly folded and will be prone for prote-
osomal degradation. This will cause lesser protein trafficking, glycosylation and presence at the cell surface, finally 
lesser activity. This decrease in activity may increase the SUA level more in T2DM subjects than normoglycemics 
(Fig. 3). So far by our knowledge, there is no study to show evidence for T2DM interaction with SLC2A9 and 
ABCG2 genotypes. The observation regarding modulation in effect size of SUA associated variants in T2DM 
patients need to be confirmed in larger sample size and across different population. Possibility of any alternative 
mechanisms that modulates the effect of variants in SLC2A9 and ABCG2 genes under diabetic condition cannot 
be excluded.
Figure 3. Mode of action of variants in ABCG2 and SLC2A9 genes under T2DM condition. 
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Our study also showed the association of rs2078267 variant in SLC22A11 gene at genome wide significance 
level in any population outside Caucasians for the first time. SLC22A11 is a low affinity urate transporter and 
known to express in kidneys and placenta. SLC22A11 has a role in the transport of multiple organic anions33.
Allele dosage analysis suggests that accumulation of studied variants in number may heavily contribute 
towards increasing SUA level in Indians.
Our study identified three novel variants near two different long non-coding RNA genes (AL356739.1, 
AC064865.1) at sub-genome wide levels (p-value < 10−5, 10−4) (Supplementary Table S3) in normoglycemics 
subjects. Stronger association of variant rs12206002 suggests its indispensable role to play in pathophysiology of 
SUA level in Indians and various other populations. Novel variants rs993701 and rs12206002 are 123kb and 130kb 
upstream of AL356739.1 gene. Variant rs1445305 is 4.7 kb downstream of AC064865.1 gene. Functions of these 
genes are only speculative and not confirmed. The variant rs1445305 is on an enhancer mark in K562 cell line. 
This suggests a possible functional role of these variants by altering the binding of transcription related protein.
In conclusion, our study extended the association of three uric acid transporter genes with SUA level to 
Indians at genome-wide significant level. It also indicated alteration in effect size of the genetic variants associ-
ated with SUA level with disease condition like T2DM. Our study further suggests involvement of both common 
as well as population specific genetic player to determine SUA levels. Enrichment of urate metabolic process in 
significant genes represents the contribution of uric acid transporter genes in determining SUA levels in Indians. 
These observations may have implications for further research into genetics of urate signaling in Indian popula-
tion. These findings will also have possible impacts in pharmaceutical industry to understand the efficacy of urate 
lowering drug in altered condition like T2DM. The current information may also find relevance during treatment 
of patients with T2DM along with SUA related complications and may help in their better management.
Methodology
Study participants. All study participants in this study are the member of INdian DIabetes Consortium34. 
Samples are well characterized for anthropometric and biochemical parameters34 (Supplementary Table S5). 
These samples were enrolled in the study by conducting diabetes awareness camp organized in various parts of 
North India. Prior informed written consent was obtained from the study participants. The study was approved 
by the Human Ethics Committee of CSIR-Institute of Genomics and Integrative Biology and All India Institute 
of Medical Sciences research Ethics Committee. The study was conducted in accordance with the principles of 
Helsinki Declaration. Various anthropometric parameters like height, weight, waist circumference, hip circum-
ference and biochemical parameters like total cholesterol, triglyceride, HDL and LDL were measured. The uric 
acid level was measured by enzymatic colorimetric method using COBAS Integra 400 plus (Roche Diagnostic, 
Mannheim, Germany).
Discovery phase genotyping and quality control. Discovery phase samples were genotyped as a part 
of T2DM GWAS conducted in our laboratory using Illumina Human 610-quad bead chips11. Normoglycemic 
individuals used as control for T2DM GWAS were analyzed for current study. Genotype of these samples has 
been called by Gene call algorithm using Genome studio software. Strong quality control (both samples and 
SNPs) were performed on data. Samples were excluded based on call rate (< 95%), heterozygosity (Samples with 
observed heterozygosity value 3 SD away from the mean heterozygosity were removed) and sex-discrepancy. 
Related samples were removed based on Identity-by-descent analysis (Pi-hat> 0.1875). Cryptic relatedness for 
samples was calculated using 1,17,982 pruned SNPs. Pruning of the SNPs was done by applying –indep-pairwise 
command with a r2 0.2 and window size of 50 using PLINK v1.07 (http://pngu.mgh.harvard.edu/~purcell/
plink)35. Population outliers were detected using principal component analysis (http://www.complextraitgenom-
ics.com/software/gcta/)36. First five principal components were used to detect population outlier samples. A total 
of 27 samples having eigenvectors 6 standard deviation away from the mean value were removed as outliers. 
SNPs with call rate (< 97%), Hardy Weinberg equilibrium (p-value < 10−5) and MAF < 0.01 were removed. We 
also removed SNPs in sex and mitochondrial chromosomes. Details for quality control steps have been given as 
Supplementary Fig. S4.
Samples with SUA level 3 standard deviations away of mean value were considered as outliers and were 
removed from the analysis. SUA levels were converted in to standard unit (μ mol/L) and then inverse normalized 
using inbuilt command in R (http://www.r-project.org/). Association of SNPs with inverse normalized SUA levels 
was tested using linear regression model in PLINK. Sex, age, BMI and first three principal components were used 
as covariates in the model. To find the deviation of p-values obtained from an additive model a quantile-quantile 
(QQ) plot for –log (p-value) against theoretical p-value was plotted using qqman package in R.
Validation phase genotyping and meta-analysis. Genetic markers from discovery phase having 
p-value < 10−4, in addition to known signals associated with SUA levels were taken for validation phase. The 
selected markers were genotyped along with other markers selected for ongoing GWAS for other quantitative 
traits in our laboratory using GoldenGate technology (Illumina San Diago, USA) and were analyzed in 3,725 
Indians. A total of 204 samples (5.47%) were genotyped in duplicate, error rate of < 0.01 was detected. Samples 
were removed having call rate < 90%. SNPs with GenTran score < 0.60, cluster separation score < 0.4 and call 
rate < 90% were excluded. We also excluded SNPs with minor allele frequency < 0.01 and Hardy-Weinberg 
Equilibrium p-value < 10−5. Samples with SUA level 3 standard deviations away from mean value were removed. 
SUA level was converted to standard unit and was inverse normalized before association. Association analysis was 
performed using linear regression model and model was adjusted for age, sex and BMI. Conditional analysis for 
loci in SLC2A9 was done in the merged healthy samples using PLINK and model was adjusted for age, sex and 
BMI as covariates. Meta-analysis of the summary statistics of the stage 1 and stage 2 results was done by METAL 
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(ttp://www.sph.umich.edu/csg/abecasis/Metal/) using fixed effect inverse variance method37. All analyses have 
been done in healthy subjects if not stated otherwise.
We have also done joint analysis of both discovery phase and replication phase normoglycemic and T2DM 
subjects in seeking for association of some additional signals with SUA level. Joint analysis was done using linear 
regression and model was adjusted for age, sex, BMI and T2DM status.
Enrichment analysis of the significant genes. To identify the functional contribution of the genes sig-
nificantly associated with SUA levels, enrichment analysis was performed using GeneMANIA (http://www.gene-
mania.org/)38. Enrichment for function of significant genes (p-value < 0.05) obtained during meta-analysis of 
normoglycemic subjects was done by searching for functions in GeneMANIA with pathway as network. Features 
with FDR corrected p-value < 0.05 were considered significant.
In-silico Analysis of effect size of SUA associated variants in European ancestry subjects. The 
top three novel signals obtained from meta-analysis of stage 1 and stage 2 results in Indians were tested for asso-
ciation with SUA level using genome wide data from Australian Twin-Family Study (AUSTWIN) consortium 
in Australian samples of European origin39. AUSTWIN now includes 11741 adult participants (twins and their 
family members) with genotyping and uric acid results. Meta-analysis by combining the summary statistics for 
association in normolycemic subjects, T2DM subjects and AUSTWIN subjects was done by METAL. The effect 
sizes were converted to uniform unit by proper conversion factor before meta-analysis.
Analysis of effect size of SUA associated variants in T2DM subjects. To determine possible dif-
ference in the impact of SUA associated genetic variants in diabetic conditions, we examined the effect size of 
markers associated with uric acid level at genome wide significance level in 1,077 T2DM subjects. We selected 
only those markers that were associated with SUA level (p-value< 0.05) in both T2DM subjects and normogly-
cemic subjects. Data were analyzed separately for T2DM similar to normoglycemic subjects and effect size was 
estimated as mentioned above. Cohen’s d (d) value was calculated to compare the effect size. Cohen’s d was cal-
culated as the ratio of difference of effect size between T2DM and normoglycemic divided by pooled variance of 
the two effect sizes.
Combined risk score analysis. To find the cumulative affect of SUA increasing alleles for studied GWAS 
variant, effective unweighted genetic risk score was calculated. Genotypes were coded as 0, 1 and 2 based upon 
presence of zero, single or double SUA increasing allele in a subject. The effective genetic score was calculated as 
sum of scores for all six variants. To study the comparative enhancement in SUA level, subjects were divided into 
< 2, 2–3, 4–5, 6–7, 8–9 and 10–11 genetic score containing groups. Mean value of SUA level was calculated and 
plotted against genetic score.
Power calculation. Power of the study was calculated using Quanto software (http://hydra.usc.edu/gxe/) 
assuming additive genetic model for a range of allele frequencies from 0.001–0.5. Two tailed test at significance 
level of 0.05 with effect size ranging from 10.50–16.50 obtained from literature was used for power calculation 
and it was found that present study is sufficiently powered to detect association of genetic variants. A urate level of 
308 μ mol/L and standard deviation of 91 μ mol/L was used. MAF for combined samples and calculated effect size 
from meta-analysis was used for final power analysis.
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